711 results on '"Hong, W. K."'
Search Results
102. Primary Chemotherapy of Advanced Head and Neck Cancer: Where Do We Go From Here?
103. p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma
104. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
105. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
106. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors.
107. Laryngeal Preservation for Advanced Laryngeal and Hypopharyngeal Cancers
108. Toxicity of Isotretinoin in a Chemoprevention Trial to Prevent Second Primary Tumours Following Head and Neck Cancer
109. Mutagen Sensitivity as a Risk Factor for Second Malignant Tumors Following Malignancies of the Upper Aerodigestive Tract
110. 13-cis-Retinoic Acid Plus Interferon- 2a in Recurrent Respiratory Papillomatosis
111. A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer
112. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.
113. Cancer chemoprevention.
114. Prevention of Second Primary Tumors With Isotretinoin in Patients With Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up
115. Detection of Chromosomal Polysomy in Oral Leukoplakia, a Premalignant Lesion
116. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma.
117. Clinical Chemoprevention: Developing a Cancer Prevention Strategy
118. Not yet standard: retinoids versus second primary tumors.
119. Sequential Increases in Proliferating Cell Nuclear Antigen Expression in Head and Neck Tumorigenesis: A Potential Biomarker
120. Response
121. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.
122. 13-cis-Retinoic Acid Plus Interferon- 2a in Locally Advanced Squamous Cell Carcinoma of the Cervix
123. Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
124. Warfarin and small-cell lung cancer.
125. Overview of Combined Modality Therapies for Head and Neck Cancer
126. Regression of Oral Leukoplakia With -Tocopherol: A Community Clinical Oncology Program Chemoprevention Study
127. Chemoprevention strategies in lung carcinogenesis
128. The incidence of second primary tumors in long-term survivors of small-cell lung cancer.
129. Improved Therapeutic Index by Leucovorin of Edatrexate, Cyclophosphamide, and Cisplatin Regimen for Non-Small-Cell Lung Cancer
130. 13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix
131. 13-cis-Retinoic Acid and Interferon -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin
132. A framework for process maintenance (software).
133. A comprehensive process model for studying software process papers.
134. Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.
135. Beta-Carotene Didn't Prevent Cancer: What's Up Doc?
136. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma.
137. Biomarkers as Intermediate End Points in Chemoprevention Trials
138. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
139. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.
140. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
141. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk.
142. Adenocarcinoma of the lung in young patients: the M. D. Anderson experience.
143. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck.
144. Combination of cis-platinum and bleomycin prior to surgery and/or radiotherapy compared with radiotherapy alone for the treatment of advanced squamous cell carcinoma of the head and neck.
145. Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion.
146. The tight-coupled monopole (TCM) and tight-coupled tandem (TCT) attenuators: Theoretical aspects and experimental attenuation in an air duct.
147. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.
148. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung.
149. Association of the Epstein-Barr virus with lymphoepithelioma of the thymus.
150. Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.